According to the GAPP2™ (Global Attitudes of Patients and Physicians) survey, funded by Novo Nordisk and presented today at the Annual Meeting of the European Association for the Study of Diabetes (EASD), four out of five (80%) people with type 2 diabetes have experienced self-treated hypoglycemia… Read more
Data from two new studies shows patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycemia when using degludec, Novo Nordisk’s ultra-long-acting insulin, compared with those using insulin glargine (Lantus).
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s ultra-long acting insulin, insulin degludec, for treatment of diabetes.
Insulin degludec, marketed globally under the name Tresiba, is a new generation of once-daily basal insulin, which has been discovered and developed by Novo Nordisk. Read more
Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to compare semaglutide with a once-weekly formulation of liraglutide being studied in phase 1 trials before selecting a candidate for phase 3 development. Liraglutide is the … Read more
JDRF and Novo Nordisk have announced that they are partnering in an attempt to discover and develop novel immunotherapies to prevent, treat, and help cure type 1 diabetes. The collaboration between JDRF and Novo Nordisk will focus on research originating from … Read more
New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of HbA1c levels when using Victoza compared to Byetta (exenatide) and DPP-4 inhibitors. Victoza… Read more
The U.S. FDA has informed Novo Nordisk that a three-month extension period was required in order to complete its regulatory review of the new drug applications (NDA) for the ultra-long-acting insulins degludec and insulin degludec/insulin aspart… Read more
The U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes, making it the first and only basal insulin analog for use in this young patient group. With the expansion of its pediatric indication… Read more
Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.
The two studies included in total 1,635 participants and investigated insulin degludec compared to insulin… Read more
Dr. Jovanovic even recommends using Levemir injections at night to women using insulin pumps, as she prefers the assurance of a basal shot… Read more